OSPRI Emerges from Merger to Revolutionize Infectious Disease Testing with Integrated PCR Platform

The biotechnology landscape has been reshaped by the merger of Community Direct DX, Scienetix, and the R&D division of Advanta Genetics to form OSPRI, creating one of the world's first fully vertically-integrated molecular testing platforms. This new entity specializes in polymerase chain reaction (PCR)-based infectious disease detection, developing advanced tools that improve access to high-quality care across multiple healthcare segments including women's health, primary care, urgent care, urology, hospitals, and clinical reference laboratories.

OSPRI delivers a comprehensive end-to-end solution that covers manufacturing, lab buildout, revenue cycle management, and regulatory support, empowering healthcare providers to operate high-complexity laboratories in-house with enhanced speed, accuracy, and financial control. Steve M. Sorey, Partner at OSPRI, emphasized the company's mission, stating that PCR testing's cost and complexity have historically limited widespread adoption, and OSPRI is focused on making the technology faster, cheaper, and more accessible for all stakeholders.

The merger is supported by up to $30 million in strategic funding from Catalio Capital Management, a leading healthcare investment firm with deep expertise in diagnostics. Jonathan Blankfein, Partner at Catalio, noted that OSPRI provides a powerful solution for physician groups and laboratories by simplifying infectious disease testing while creating strong clinical and commercial value, supporting the mission to expand access to rapid, provider-centric diagnostics.

OSPRI's technological advancements are substantial, featuring a 20–50% reduction in overall testing costs, a 50–70% decrease in testing time and workflow steps, up to a 4x increase in testing capacity, and customized assays tailored to provider specialty and patient population. The platform also reduces lab errors through simplified workflows and offers a comprehensive menu of 80+ PCR tests covering 250+ pathogens and antimicrobial resistance genes.

The company's scientific leadership includes Dr. Rahul Sharma as Chief Science Officer, Dr. Sadia Almas as Chief Innovation Officer, and Dr. Alaina Vincent as Chief Clinical Officer. Building on a legacy of innovation, OSPRI combines the complementary strengths of its founding entities: Community Direct DX, which has launched over 60 labs nationwide since 2015; Scienetix, with deep expertise in molecular bioengineering; and Advanta R&D, known for advancements in high-resolution genomics and contributions to national public health initiatives.

Jeremy Adamic, Partner at OSPRI, highlighted the company's exponential growth in production capabilities, from a limited menu and basic quality control to delivering over 40,000 tests per day with multilayered quality control, scaling both volume and reliability. Over the next 12–24 months, OSPRI plans to expand its R&D team by 40% and grow commercial operations by 25% to meet increasing demand. Headquartered in McKinney, Texas, the company currently serves clients across 20 states and multiple clinical specialties.

Dr. Alaina Vincent reinforced OSPRI's core objective of solving real problems of cost and complexity in infectious disease testing, advocating for accessible innovation that enables better, faster care for more patients by equipping providers with necessary tools. This merger and the resulting integrated platform represent a significant advancement in diagnostic technology, potentially transforming how infectious diseases are detected and managed across healthcare systems worldwide. More information about OSPRI can be found at www.OspriBio.com.